Magnitude of Phenotypic and MTBDRplus Line Probe Assay First-Line Anti-Tuberculosis Drug Resistance Among Tuberculosis Patients; Northwest Ethiopia

References

• Pitso L, Potgieter S, Van der Spoel van Dijk A. Prevalence of isoniazid resistance-conferring mutations associated with multidrug-resistant tuberculosis in Free State Province, South Africa. S Afr Med J. 2019;109:659–664. doi:10.7196/SAMJ.2019.v109i9.1373031635590
   PubMed Web of Science ®Google Scholar
• Salindri AD, Sales RF, DiMiceli L, et al. Isoniazid monoresistance and rate of culture conversion among patients in the state of Georgia with confirmed tuberculosis, 2009–2014. Ann Am Thorac Soc. 2018;15:331–340. doi:10.1513/AnnalsATS.201702-147OC29131662
   PubMed Web of Science ®Google Scholar
• Sayadi M, Zare H, Jamedar SA, et al. Genotypic and phenotypic characterization of Mycobacterium tuberculosis resistance against fluoroquinolones in the northeast of Iran. BMC Infect Dis. 2020;20:390. doi:10.1186/s12879-020-05112-532487030
   PubMed Web of Science ®Google Scholar
• Nieto Ramirez LM, Ferro BE, Diaz G, et al. Genetic profiling of Mycobacterium tuberculosis revealed “modern” Beijing strains linked to MDR-TB from Southwestern Colombia. PLoS One. 2020;15:e0224908. doi:10.1371/journal.pone.022490832330146
   PubMed Web of Science ®Google Scholar
• Lobie TA, Woldeamanuel Y, Asrat D, et al. Genetic diversity and drug resistance pattern of Mycobacterium tuberculosis strains isolated from pulmonary tuberculosis patients in the Benishangul Gumuz region and its surroundings, Northwest Ethiopia. PLoS One. 2020;15:e0231320. doi:10.1371/journal.pone.023132032267877
   PubMed Web of Science ®Google Scholar
• Jhun BW, Koh WJ. Treatment of isoniazid-resistant pulmonary tuberculosis. Tuberc Respir Dis (Seoul). 2020;83:20–30. doi:10.4046/trd.2019.006531905429
   PubMed Web of Science ®Google Scholar
• Haile B, Tafess K, Zewude A, et al. Spoligotyping and drug sensitivity of Mycobacterium tuberculosis isolated from pulmonary tuberculosis patients in the Arsi Zone of southeastern Ethiopia. New Microbes New Infect. 2020;33:100620. doi:10.1016/j.nmni.2019.10062031908780
   PubMed Web of Science ®Google Scholar
• Edwards BD, Edwards J, Cooper R, et al. Incidence, treatment, and outcomes of isoniazid mono-resistant Mycobacterium tuberculosis infections in Alberta, Canada from 2007–2017. PLoS One. 2020;15:e0229691. doi:10.1371/journal.pone.022969132155169
   PubMed Web of Science ®Google Scholar
• Tembo BP, Malangu NG. Prevalence and factors associated with multidrug/rifampicin resistant tuberculosis among suspected drug resistant tuberculosis patients in Botswana. BMC Infect Dis. 2019;19:779. doi:10.1186/s12879-019-4375-731492099
   PubMed Web of Science ®Google Scholar
• WHO. WHO global tuberculosis report. 2020.
   Google Scholar
• Kazemian H, Kardan-Yamchi J, Bahador A, et al. Efficacy of line probe assay in detection of drug-resistant pulmonary tuberculosis in comparison with GeneXpert and phenotypic methods in Iran and genetic analysis of isolates by MIRU-VNTR. Infect Drug Resist. 2019;12:3585–3593. doi:10.2147/IDR.S22290531814746
   PubMed Web of Science ®Google Scholar
• Merker M, Kohl TA, Barilar I, et al. Phylogenetically informative mutations in genes implicated in antibiotic resistance in Mycobacterium tuberculosis complex. Genome Med. 2020;12:27. doi:10.1186/s13073-020-00726-532143680
   PubMed Web of Science ®Google Scholar
• Swain SS, Sharma D, Hussain T, et al. Molecular mechanisms of underlying genetic factors and associated mutations for drug resistance in Mycobacterium tuberculosis. Emerg Microbes Infect. 2020;9:1651–1663. doi:10.1080/22221751.2020.178533432573374
   PubMed Web of Science ®Google Scholar
• Gunar G. Multidrug-resistant and extensively drug-resistant tuberculosis: a review of current concepts and future challenges. Clin Med (Northfield Il). 2014;14:279–285. doi:10.7861/clinmedicine.14-3-279
   Web of Science ®Google Scholar
• Timire C, Metcalfe JZ, Chirenda J, et al. Prevalence of drug-resistant tuberculosis in Zimbabwe: a health facility-based cross-sectional survey. Int J Infect Dis. 2019;87:119–125. doi:10.1016/j.ijid.2019.07.02131357057
   PubMed Web of Science ®Google Scholar
• Kang JY, Hur J, Kim S, et al. Clinical implications of discrepant results between genotypic MTBDRplus and phenotypic Lowenstein-Jensen method for isoniazid or rifampicin drug susceptibility tests in tuberculosis patients. J Thorac Dis. 2019;11:400–409. doi:10.21037/jtd.2019.01.5830962983
   PubMed Web of Science ®Google Scholar
• Torrea G, Ng KCS, Van Deun A, et al. Variable ability of rapid tests to detect Mycobacterium tuberculosis rpoB mutations conferring phenotypically occult rifampicin resistance. Sci Rep. 2019;9:11826. doi:10.1038/s41598-019-48401-z31413308
   PubMed Web of Science ®Google Scholar
• Mahomed S, Mlisana K, Cele L, et al. Discordant line probe genotypic testing vs culture-based drug susceptibility phenotypic testing in TB endemic KwaZulu-Natal: impact on bedside clinical decision making. J Clin Tuberc Other Mycobact Dis. 2020;20:100176. doi:10.1016/j.jctube.2020.10017632793816
   PubMedGoogle Scholar
• Hirama T, Sabur N, Derkach P, et al. Risk factors for drug-resistant tuberculosis at a referral centre in Toronto, Ontario, Canada: 2010–2016. Can Commun Dis Rep. 2020;46:84–92. doi:10.14745/ccdr.v46i04a0532281986
   PubMedGoogle Scholar
• Bedewi Omer Z, Mekonnen Y, Worku A, et al. Evaluation of the GenoType MTBDRplus assay for detection of rifampicin- and isoniazid-resistant Mycobacterium tuberculosis isolates in central Ethiopia. Int J Mycobacteriol. 2016;5:475–481. doi:10.1016/j.ijmyco.2016.06.00527931690
   PubMedGoogle Scholar
• Yakrus MA, Driscoll J, McAlister A, et al. Molecular and growth-based drug susceptibility testing of Mycobacterium tuberculosis complex for ethambutol resistance in the United States. Tuberc Res Treat. 2016;2016:3404860. doi:10.1155/2016/340486027375902
   PubMedGoogle Scholar
• WHO. WHO global tuberculosis report. 2019.
   Google Scholar
• GLI. Mycobacteriology-Laboratory-Manual. First ed. 2014.
   Google Scholar
• Hain Lifescience. GenoType MTBDRplus VER 2.0 [Instructions for use]; IFU-304A-06; 2015. Available from: https://www.hain-lifescience.de/include_datei/kundenmodule/packungsbeilage/download.php?id=936.
   Google Scholar
• FMOH. Guidelines for Management of TB, DR-TB and Leprosy in Ethiopia. Sixth ed. 2018.
   Google Scholar
• Abate D, Taye B, Abseno M, et al. Epidemiology of anti-tuberculosis drug resistance patterns and trends in tuberculosis referral hospital in Addis Ababa, Ethiopia. BMC Res Notes. 2012;5:462. doi:10.1186/1756-0500-5-46222929063
   PubMedGoogle Scholar
• Flores-Trevino S, Morfin-Otero R, Rodriguez-Noriega E, et al. Characterization of phenotypic and genotypic drug resistance patterns of Mycobacterium tuberculosis isolates from a city in Mexico. Enferm Infecc Microbiol Clin. 2015;33:181–185. doi:10.1016/j.eimc.2014.04.00524953252
   PubMed Web of Science ®Google Scholar
• Huong N, Lan N, Cobelens F, et al. Antituberculosis drug resistance in the South of Vietnam: prevalence and trends. J Infect Dis. 2006;194:1226–1232. doi:10.1086/50790617041848
   PubMed Web of Science ®Google Scholar
• Tessema B, Beer J, Emmrich F, et al. First- and second-line anti-tuberculosis drug resistance in Northwest Ethiopia. Int J Tuberc Lung Dis. 2012;16:805–811. doi:10.5588/ijtld.11.052222390880
   PubMed Web of Science ®Google Scholar
• Aung WW, Ei PW, Nyunt WW, et al. Phenotypic and genotypic analysis of anti-tuberculosis drug resistance in Mycobacterium tuberculosis isolates in Myanmar. Ann Lab Med. 2015;35:494–499. doi:10.3343/alm.2015.35.5.49426206685
   PubMed Web of Science ®Google Scholar
• Esmael A, Ali I, Agonafir M, et al. Drug resistance pattern of Mycobacterium tuberculosis in Eastern Amhara Regional State, Ethiopia. J Microb Biochem Technol. 2014;6:75–79. doi:10.4172/1948-5948.1000125
   Google Scholar
• Brhane M, Kebede A, Petros Y. Molecular detection of multidrug-resistant tuberculosis among smear-positive pulmonary tuberculosis patients in Jigjiga town, Ethiopia. Infect Drug Resist. 2017;10:75–83. doi:10.2147/IDR.S12790328331348
   PubMed Web of Science ®Google Scholar
• Forson A, Kudzawu S, Kwara A, et al. High frequency of first-line anti-tuberculosis drug resistance among persons with chronic pulmonary tuberculosis at a teaching hospital chest clinic. Ghana Med J. 2010;44:42–46. doi:10.4314/gmj.v44i2.6885821327002
   PubMedGoogle Scholar
• Belay T, Joerg B, Frank E, et al. Analysis of gene mutations associated with isoniazid, rifampicin and ethambutol resistance among Mycobacterium tuberculosis isolates from Ethiopia. BMC Infect Dis. 2012;12:1–7. doi:10.1186/1471-2334-12-33722214291
   PubMed Web of Science ®Google Scholar
• Wondale B, Medhin G, Abebe G, et al. Phenotypic and genotypic drug sensitivity of Mycobacterium tuberculosis complex isolated from South Omo Zone, Southern Ethiopia. Infect Drug Resist. 2018;11:1581–1589. doi:10.2147/IDR.S16508830288068
   PubMed Web of Science ®Google Scholar
• André E, Goeminne L, Cabibbe A, et al. Consensus numbering system for the rifampicin resistance-associated rpoB gene mutations in pathogenic mycobacteria. Clin Microbiol Infect. 2017;23:167–172. doi:10.1016/j.cmi.2016.09.00627664776
   PubMed Web of Science ®Google Scholar
• Kebede A, Demisse D, Assefa M, et al. Performance of MTBDRplus assay in detecting multidrug resistant tuberculosis at hospital level. BMC Res Notes. 2017;10:661. doi:10.1186/s13104-017-2989-729191227
   PubMedGoogle Scholar
• Meaza A, Kebede A, Yaregal Z, et al. Evaluation of genotype MTBDRplus VER 2.0 line probe assay for the detection of MDR-TB in smear positive and negative sputum samples. BMC Infect Dis. 2017;17:280. doi:10.1186/s12879-017-2389-628415989
   PubMed Web of Science ®Google Scholar